Kisqali — Cigna
Breast Cancer – Recurrent or Metastatic in Men
Initial criteria
- Patient is age ≥ 18 years; AND
- Patient has recurrent or metastatic disease; AND
- Patient has hormone receptor-positive (HR+) [i.e., estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+)] disease; AND
- Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer; AND
- Patient is receiving a gonadotropin-releasing hormone (GnRH) analog.
Approval duration
1 year